368 related articles for article (PubMed ID: 18394015)
21. Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET.
Rischke HC; Benz MR; Wild D; Mix M; Dumont RA; Campbell D; Seufert J; Wiech T; Rössler J; Weber WA; Neumann HP
J Nucl Med; 2012 Sep; 53(9):1352-8. PubMed ID: 22836345
[TBL] [Abstract][Full Text] [Related]
22. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas.
Imani F; Agopian VG; Auerbach MS; Walter MA; Imani F; Benz MR; Dumont RA; Lai CK; Czernin JG; Yeh MW
J Nucl Med; 2009 Apr; 50(4):513-9. PubMed ID: 19289420
[TBL] [Abstract][Full Text] [Related]
23. Role of 18F-DOPA PET/CT in diagnosis and follow-up of adrenal and extra-adrenal paragangliomas.
Bacca A; Chiacchio S; Zampa V; Carrara D; Duce V; Congregati C; Simi P; Taddei S; Materazzi G; Volterrani D; Mariani G; Bernini G
Clin Nucl Med; 2014 Jan; 39(1):14-20. PubMed ID: 24300347
[TBL] [Abstract][Full Text] [Related]
24. Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma.
Rufini V; Treglia G; Castaldi P; Perotti G; Calcagni ML; Corsello SM; Galli G; Fanti S; Giordano A
Nucl Med Commun; 2011 Jul; 32(7):575-82. PubMed ID: 21471850
[TBL] [Abstract][Full Text] [Related]
25. False-positive findings on 6-[18F]fluor-l-3,4-dihydroxyphenylalanine PET (
Berends AMA; Kerstens MN; Bolt JW; Links TP; Korpershoek E; de Krijger RR; Walenkamp AME; Noordzij W; van Etten B; Kats-Ugurlu G; Brouwers AH; van der Horst-Schrivers ANA
Eur J Endocrinol; 2018 Aug; 179(2):125-133. PubMed ID: 29875288
[TBL] [Abstract][Full Text] [Related]
26. [11C]metahydroxyephedrine and [18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma.
Mann GN; Link JM; Pham P; Pickett CA; Byrd DR; Kinahan PE; Krohn KA; Mankoff DA
Ann Surg Oncol; 2006 Feb; 13(2):187-97. PubMed ID: 16418883
[TBL] [Abstract][Full Text] [Related]
27.
Kroiss AS; Uprimny C; Shulkin BL; Gruber L; Frech A; Jazbec T; Girod PP; Url C; Thomé C; Riechelmann H; Sprinzl GM; Fraedrich G; Virgolini IJ
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(2):94-99. PubMed ID: 30630744
[TBL] [Abstract][Full Text] [Related]
28. Quantitative analysis of normal and pathologic adrenal glands with 18F-FDOPA PET/CT: focus on pheochromocytomas.
Moreau A; Giraudet AL; Kryza D; Borson-Chazot F; Bournaud C; Mognetti T; Lifante JC; Combemale P; Giammarile F; Houzard C
Nucl Med Commun; 2017 Sep; 38(9):771-779. PubMed ID: 28704339
[TBL] [Abstract][Full Text] [Related]
29. (18)F-DOPA PET/CT and MRI: description of 12 histologically-verified pheochromocytomas.
Magnaldi S; Mayerhoefer ME; Khameneh A; Schuetz M; Javor D; Mitterhauser M; Dudczak R; Hacker M; Karanikas G
Anticancer Res; 2014 Feb; 34(2):791-5. PubMed ID: 24511014
[TBL] [Abstract][Full Text] [Related]
30. Utility of FDG-PET imaging in screening for succinate dehydrogenase B and D mutation-related lesions.
Kornaczewski ER; Pointon OP; Burgess JR
Clin Endocrinol (Oxf); 2016 Aug; 85(2):172-9. PubMed ID: 26776272
[TBL] [Abstract][Full Text] [Related]
31. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations.
Zelinka T; Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Reynolds JC; Ling A; Eisenhofer G; Lazúrová I; Adams KT; Whatley MA; Widimsky J; Pacak K
Endocr Relat Cancer; 2008 Mar; 15(1):311-23. PubMed ID: 18310297
[TBL] [Abstract][Full Text] [Related]
32. FDG PET in the evaluation of phaeochromocytoma: a correlative study with MIBG scintigraphy and Ki-67 proliferative index.
Lin M; Wong V; Yap J; Jin R; Leong P; Campbell P
Clin Imaging; 2013; 37(6):1084-8. PubMed ID: 24035263
[TBL] [Abstract][Full Text] [Related]
33. Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy.
King KS; Chen CC; Alexopoulos DK; Whatley MA; Reynolds JC; Patronas N; Ling A; Adams KT; Xekouki P; Lando H; Stratakis CA; Pacak K
J Clin Endocrinol Metab; 2011 Sep; 96(9):2779-85. PubMed ID: 21752889
[TBL] [Abstract][Full Text] [Related]
34. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.
Chen W; Silverman DH; Delaloye S; Czernin J; Kamdar N; Pope W; Satyamurthy N; Schiepers C; Cloughesy T
J Nucl Med; 2006 Jun; 47(6):904-11. PubMed ID: 16741298
[TBL] [Abstract][Full Text] [Related]
35. Localization and prediction of malignant potential in recurrent pheochromocytoma/paraganglioma (PCC/PGL) using 18F-FDG PET/CT.
Fikri AS; Kroiss A; Ahmad AZ; Zanariah H; Lau WF; Uprimny C; Donnemiller E; Kendler D; Nordin AJ; Virgolini IJ
Acta Radiol; 2014 Jun; 55(5):631-40. PubMed ID: 24037430
[TBL] [Abstract][Full Text] [Related]
36.
Feral CC; Tissot FS; Tosello L; Fakhry N; Sebag F; Pacak K; Taïeb D
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):812-821. PubMed ID: 27900521
[TBL] [Abstract][Full Text] [Related]
37. Characterization of neuroblastic tumors using 18F-FDOPA PET.
Lu MY; Liu YL; Chang HH; Jou ST; Yang YL; Lin KH; Lin DT; Lee YL; Lee H; Wu PY; Luo TY; Shen LH; Huang SF; Liao YF; Hsu WM; Tzen KY;
J Nucl Med; 2013 Jan; 54(1):42-9. PubMed ID: 23213196
[TBL] [Abstract][Full Text] [Related]
38. 6-[F-18]fluoro-L-DOPA positron emission tomography in the imaging of Merkel cell carcinoma: preliminary report of three cases with 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography or pentetreotide-(111In) SPECT data.
Talbot JN; Kerrou K; Missoum F; Grahek D; Aide N; Lumbroso J; Montravers F
Mol Imaging Biol; 2005; 7(4):257-61. PubMed ID: 16082495
[TBL] [Abstract][Full Text] [Related]
39. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.
Fiebrich HB; Brouwers AH; Kerstens MN; Pijl ME; Kema IP; de Jong JR; Jager PL; Elsinga PH; Dierckx RA; van der Wal JE; Sluiter WJ; de Vries EG; Links TP
J Clin Endocrinol Metab; 2009 Oct; 94(10):3922-30. PubMed ID: 19622618
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of adrenal masses using 18 F-FDOPA PET/CT in patients suspected with pheochromocytoma.
Kim SJ; Park CY; Kwon H; Kim YH
Nucl Med Commun; 2024 Jan; 45(1):86-92. PubMed ID: 37901929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]